Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (371-380 of 743) with videos related to

Pageof 75
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 24, 2016
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?Stefan Diem, Fabienne Keller, Reinhard Rüesch, et al.
Nature Medicine|July 4, 2018
Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapyCarsten Krieg, Malgorzata Nowicka, Silvia Guglietta, et al.
Dermatology (Basel, Switzerland)|September 8, 2007
S-100B and FDG-PET/CT in therapy response assessment of melanoma patientsKlaus Strobel, Jeannine Skalsky, Hans C Steinert, et al.
Melanoma Research|January 19, 2017
Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?Silvia A Haueis, Pascale Kränzlin, Joanna Mangana, et al.
Dermatopathology (Basel, Switzerland)|February 26, 2019
Keratinocytic Malfunction as a Trigger for the Development of Solar LentiginesMarjam Jeanette Barysch, Ralph Peter Braun, Isabel Kolm, et al.
Cancer Research|April 12, 2013
Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesisFrank Rolfs, Marcel Huber, Florian Gruber, et al.
Melanoma Research|December 21, 2023
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanomaNatalia M Roshardt Prieto, Patrick Turko, Caroline Zellweger, et al.
Cancer Research|March 12, 2011
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growthGianluca Civenni, Anne Walter, Nikita Kobert, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2013
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot studyReinhard Dummer, Simone M Goldinger, Christian P Turtschi, et al.
The Journal of Investigative Dermatology|March 12, 2013
Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switchingDaniel S Widmer, Keith S Hoek, Phil F Cheng, et al.
Pageof 75

Showing results (371-380 of 743) with videos related to

Sort By:
Pageof 75
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 24, 2016
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?Stefan Diem, Fabienne Keller, Reinhard Rüesch, et al.
Nature Medicine|July 4, 2018
Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapyCarsten Krieg, Malgorzata Nowicka, Silvia Guglietta, et al.
Dermatology (Basel, Switzerland)|September 8, 2007
S-100B and FDG-PET/CT in therapy response assessment of melanoma patientsKlaus Strobel, Jeannine Skalsky, Hans C Steinert, et al.
Melanoma Research|January 19, 2017
Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?Silvia A Haueis, Pascale Kränzlin, Joanna Mangana, et al.
Dermatopathology (Basel, Switzerland)|February 26, 2019
Keratinocytic Malfunction as a Trigger for the Development of Solar LentiginesMarjam Jeanette Barysch, Ralph Peter Braun, Isabel Kolm, et al.
Cancer Research|April 12, 2013
Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesisFrank Rolfs, Marcel Huber, Florian Gruber, et al.
Melanoma Research|December 21, 2023
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanomaNatalia M Roshardt Prieto, Patrick Turko, Caroline Zellweger, et al.
Cancer Research|March 12, 2011
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growthGianluca Civenni, Anne Walter, Nikita Kobert, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2013
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot studyReinhard Dummer, Simone M Goldinger, Christian P Turtschi, et al.
The Journal of Investigative Dermatology|March 12, 2013
Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switchingDaniel S Widmer, Keith S Hoek, Phil F Cheng, et al.
Pageof 75